Pharmacological Prevention and Treatment in Clinical At-Risk States for Psychosis

Author(s): Stephan Ruhrmann , Joachim Klosterkotter , Mitja Bodatsch , Andreas Bechdolf , Benno Graf Schimmelmann , Alexandra Nikolaides , Desiree Hilboll , Frauke Schultze-Lutter .

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 4 , 2012


Over the last couple of decades, the treatment of psychoses has much advanced; yet, despite all progress, the individual and societal burden associated with psychosis and particularly schizophrenia has largely remained unchanged. Therefore, much hope is currently placed on indicated prevention as a mean to fight these burdens before they set in. Though the number of studies investigating pharmacological interventions is still limited, encouraging results have been reported from the pioneering trials, despite several methodological limitations. Furthermore, it has become clear that persons characterized by the at-risk criteria are already ill and do not only need preventive intervention, but also treatment. In consequence, outcome criteria have to be broadened to cover the current needs of the patients. As is indicated by a recent study successfully using Omega-3 fatty acids for both purposes, it may be promising to develop and investigate interventions especially for the at-risk state, independent of their effectiveness in manifest disease states. Treatment studies may become promoted by the proposed introduction of a new disorder category into DSM-V. Future prevention studies, however, need to solve the challenge of changing immediate transition rates, demanding for new risk enrichment strategies as a prerequisite for feasible trial designs.

Keywords: At-risk, early intervention, prevention, psychosis, antipsychotics, antidepressants, omega-3 fatty acids, schizophrenia, DSM-V, sub-psychotic symptoms

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [550 - 557]
Pages: 8
DOI: 10.2174/138161212799316172
Price: $58

Article Metrics

PDF: 12